Frank Yocca

Frank Yocca is a declared insider of BioXcel Therapeutics, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 20 January 2023 to 15 June 2026, the count stands at 20 filings.

The open-market record consists of 2 sales worth €1.4M, with no purchase. Other entries cover 2 share grants and 16 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

On 17 June 2026 came the latest disclosure, an option exercise in BioXcel Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.